Alpha Fetoprotein and a Useful Tool for Surveillance of Interferon-Free Treated Cirrhotic Patients for Hepatocellular Carcinoma After SVR

Gheorghe, Liana; Iacob, Speranta; Prelipcean, Cristina Cijevschi; Mihai, Cătălina; Grasu, Mugur; Dumitru, Radu; Iacob, Răzvan; Lupescu, Ioana Gabriela; Pirvulescu, Iuliana; Gheorghe, Cristian

doi:10.1016/s0016-5085(17)31283-0

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are repeated every 24 weeks for 4 years in patients with mild fibrosis (F0-F2), longer in cases of F3-F4 fibrosis, and for an indefinite period of time in patients with the history of HCC. Patients with cirrhosis should also have regular upper gastrointestinal endoscopy [ 13 , 14 ].…”

Section: General Recommendationsmentioning

confidence: 99%

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020

Halota

Flisiak

Juszczyk

et al. 2020

ceh

View full text Add to dashboard Cite

Section: General Recommendationsmentioning

confidence: 99%

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020

Halota

Flisiak

Juszczyk

et al. 2020

ceh

View full text Add to dashboard Cite

“…The claims that DAA therapy increases the risk of hepatocarcinogenesis have not been proven, however HCC has been reported to occur during DAA treatment. There is no evidence to exclude the possibility that the reported cases involved the manifestation of hepatocellular carcinoma which started developing before the introduction of antiviral drugs [ 12 - 17 ]. The situation is different in HCV-infected patients with a history of HCC treatment (resection, thermoablation).…”

Section: General Recommendationsmentioning

confidence: 99%

Recommendations for the treatment of hepatitis C in 2017

Halota¹,

Flisiak²,

Juszczyk³

et al. 2017

ceh

View full text Add to dashboard Cite

The goals of treatment is to eliminate HCV infection, stop or reverse histological changes, reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the recommendation of the Polish Group of Experts for HCV in 2017 all patients with chronic HCV infection should receive treatment, but it is not recommended in patients at high risk of short overall survival. If access to therapy is restricted, priority should be given to patients whose HCV infection can lead to an unfavourable outcome of the disease within a short time frame, particular to individuals with liver cirrhosis, rapidly progressing liver fibrosis, extrahepatic manifestations of HCV infection, chronic kidney diseases, patients before and after organ transplantation. Current recommendations of Polish Group of Experts for HCV provide guidelines to select optimal medication, assessment of liver fibrosis, treatment efficacy, dealing with resistance to direct acting antivirals, monitoring for hepatocellular carcinoma, management of HBV/HCV coinfection and drug interactions. It constains also advice on treatment of special patients populations such as renal failure, liver transplant and hepatic decompensation, as well as retreatment of patients which failed interferon free therapy. Moreover specific recommendations of management patients infected with different genotypes with currently reimbursed regimens or those expected to become available shortly in Poland are also included.

show abstract

Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease

Colli

Nadarević

Miletić

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Alpha Fetoprotein and a Useful Tool for Surveillance of Interferon-Free Treated Cirrhotic Patients for Hepatocellular Carcinoma After SVR

Cited by 3 publications

References 0 publications

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020

Recommendations for the treatment of hepatitis C in 2017

Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease

Contact Info

Product

Resources

About